In patients with mild to moderate liver impairment AUC and Cmax of Vantoxyl increased 6.5 and 7.5 fold, respectively, after a single 400 mg dose of Vantoxyl extended-release tablet AUC and Cmax of the active Metabolite I also increased 6.9 and 8.2 fold, respectively, in hepatic impaired subjects. Vantoxyl extended-release tablet has not been studied in patients with severe hepatic failure.
Bleeding has been reported in patients treated with Vantoxyl with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors.
Increased prothrombin time has been reported in patients concomitantly treated with Vantoxyl and vitamin K antagonists. Monitoring of anticoagulant activity in these patients is recommended when Vantoxyl is introduced or the dose is changed.
Concomitant administration of Vantoxyl and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Monitor theophylline levels when starting Vantoxyl or changing dose.
Concomitant administration of strong CYP1A2 inhibitors (including e.g. ciprofloxacin or fluvoxamine) may increase the exposure to Vantoxyl (see ADVERSE REACTIONS).
Vantoxyl has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with Vantoxyl plus nifedipine or captopril; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced.
Postmarketing cases of increased anticoagulant activity have been reported in patients concomitantly treated with Vantoxyl and vitamin K antagonists. Monitoring of anticoagulant activity in these patients is recommended when Vantoxyl is introduced or the dose is changed.
Concomitant administration with cimetidine is reported to increase the average steady state plasma concentration of Vantoxyl (
25%) and the Metabolite I (
What special dietary instructions should I follow?
Take Vantoxyl with meals to prevent upset stomach. If symptoms continue, tell your doctor. Your dose may need to be decreased.
Vantoxyl , a methylxanthine derivative, was the first drug approved by the U.S. Food and Drug Administration (FDA) for management of intermittent claudication. The proposed mechanisms by which it might benefit claudication include decreases in blood viscosity, platelet adhesion, and fibrinogen and improvement of red blood cell deformability. The largest trial to examine the effect of Vantoxyl in intermittent claudication, the Scandinavian Study Group trial with 150 patients, failed to demonstrate a significant improvement in pain-free or maximal walking distance compared with placebo. A meta-analysis of clinical trials found that Vantoxyl has a slight but significant beneficial effect on intermittent claudication, but whether a significant benefit is achieved is controversial. 61,62
Vantoxyl is a non-selective inhibitor of cyclic-3’, 5’-phospho-diesterase (PDE), leading to a broad-spectrum effect against cell proliferation and inflammation. It also reduces the expression of adhesion molecules such as intercellular adhesion molecule-I (ICAM-I) on keratinocytes and E-selectin expression on endothelial cells.
- This medication contains Vantoxyl. Do not take Trental, Pentoxil, or Vantoxyl SR if you are allergic to Vantoxyl or any ingredients contained in this drug.
- Keep out of reach of children
- In case of overdose, get medical help or contact a Poison Control Center immediately
How to use Vantoxyl
Take this medication by mouth with food, usually 3 times daily or as directed by your doctor.
Do not crush or chew this medication. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.
Dosage is based on your medical condition and response to treatment.
Use this medication regularly in order to get the most benefit from it. To help you remember, take it at the same times each day. It is important to continue taking this medication even if you feel well. Do not stop this medication without consulting your doctor. Improvement in symptoms can occur in 2-4 weeks, but it may take up to 8 weeks to get the full benefit.
Tell your doctor if your condition persists or worsens.
Why is this medication prescribed?
Vantoxyl is used to improve blood flow in patients with circulation problems to reduce aching, cramping, and tiredness in the hands and feet. It works by decreasing the thickness (viscosity) of blood. This change allows your blood to flow more easily, especially in the small blood vessels of the hands and feet.
This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Venous leg diseases and ulcers
Vantoxyl is also used in the treatment of venous leg disease and venous ulcers, especially in patients unable to tolerate compression therapy.
The use of Vantoxyl for ischemic pain in pseudoxanthoma elasticum and other micro vascular disorders has been encouraging.
Vantoxyl may also be beneficial in other diseases such as Kimura's disease with oral ulcers, generalized granuloma annulare, sweet syndrome, pemphigus vulgaris and other bullous disorders.
Irritant and allergic hypersensitivity reactions
Various studies conducted on animals suggest a potential role of pharmacologic intervention with Vantoxyl as a means to treat contact dermatitis.